Innovative and Professional: Outlook Therapeutics Receives FDA Acceptance for ONS-5010 as Wet AMD Treatment
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Retinal Diseases Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved…